查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
急性偏頭痛治療的全球市場:各藥品類型 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1208551

急性偏頭痛治療的全球市場:各藥品類型 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Acute Migraine Treatment Market (Drug Type: Triptans, CGRP Antagonist, NSAID Drugs, Beta-adrenergic Blockers, Ergot Alkaloids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球急性偏頭痛治療市場相關調查分析，提供市場趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提條件與調查手法

第3章 摘要整理:全球急性偏頭痛治療市場

第4章 市場概要

  • 簡介
    • 藥品類型定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球急性偏頭痛治療市場分析與預測(2017年～2031年)

第5章 主要考察

  • 主要的產業活動
  • 開發平台分析
  • 法規情勢:/世界:各地區
  • COVID-19大流行病對產業的影響(價值鏈與短/中/長期的影響)

第6章 全球急性偏頭痛治療市場分析與預測:各藥品類型

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各藥品類型(2017年～2031年)
    • Triptans
    • CGRP拮抗劑
    • NSAID藥品
    • β腎上腺素阻斷劑
    • 麥角生物鹼
    • 其他
  • 市場魅力分析:各藥品類型

第7章 全球急性偏頭痛治療市場分析與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各給藥途徑(2017年～2031年)
    • 口服
    • 注射
    • 其他
  • 市場魅力分析:各給藥途徑

第8章 全球急性偏頭痛治療市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各流通管道(2017年～2031年)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第9章 全球急性偏頭痛治療市場分析與預測:各地區

  • 主要調查結果
  • 市場金額的預測:各地區(2017年～2031年)
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第10章 北美的急性偏頭痛治療市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場金額的預測:各藥品類型(2017年～2031年)
  • 市場金額的預測:各給藥途徑(2017年～2031年)
  • 市場金額的預測:各流通管道(2017年～2031年)
  • 市場金額的預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各藥品類型
    • 各給藥途徑
    • 各流通管道
    • 各國

第11章 歐洲的急性偏頭痛治療市場分析與預測

第12章 亞太地區的急性偏頭痛治療市場分析與預測

第13章 南美的急性偏頭痛治療市場分析與預測

第14章 中東·非洲的急性偏頭痛治療市場分析與預測

第15章 競爭情形

  • 市場企業 - 競爭矩陣:各等級·各企業規模
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • Teva Pharmaceutical
    • Hoffmann-La Roche Ltd.
    • Johnson and Johnson
    • Amgen
    • AstraZeneca
    • Pfizer, Inc.
    • Merck & Co.
    • Novartis AG
    • Allergan plc
    • Eli Lilly and Company
    • AbbVie
    • BioDelivery Sciences International, Inc.
Product Code: TMRGL85296

The report provides revenue of the global acute migraine treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute migraine treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute migraine treatment market.

The report delves into the competitive landscape of the global acute migraine treatment market. Key players operating in the global acute migraine treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute migraine treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Migraine Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Migraine Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Pipeline Analysis
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Acute Migraine Treatment Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Triptans
    • 6.3.2. CGRP Antagonist
    • 6.3.3. NSAID Drugs
    • 6.3.4. Beta-adrenergic Blockers
    • 6.3.5. Ergot Alkaloids
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Acute Migraine Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injection
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Acute Migraine Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Migraine Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Migraine Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017-2031
    • 10.2.1. Triptans
    • 10.2.2. CGRP Antagonist
    • 10.2.3. NSAID Drugs
    • 10.2.4. Beta-adrenergic Blockers
    • 10.2.5. Ergot Alkaloids
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Injection
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Acute Migraine Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. Triptans
    • 11.2.2. CGRP Antagonist
    • 11.2.3. NSAID Drugs
    • 11.2.4. Beta-adrenergic Blockers
    • 11.2.5. Ergot Alkaloids
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Injection
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Migraine Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. Triptans
    • 12.2.2. CGRP Antagonist
    • 12.2.3. NSAID Drugs
    • 12.2.4. Beta-adrenergic Blockers
    • 12.2.5. Ergot Alkaloids
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Injection
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Migraine Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017-2031
    • 13.2.1. Triptans
    • 13.2.2. CGRP Antagonist
    • 13.2.3. NSAID Drugs
    • 13.2.4. Beta-adrenergic Blockers
    • 13.2.5. Ergot Alkaloids
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Injection
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Migraine Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2017-2031
    • 14.2.1. Triptans
    • 14.2.2. CGRP Antagonist
    • 14.2.3. NSAID Drugs
    • 14.2.4. Beta-adrenergic Blockers
    • 14.2.5. Ergot Alkaloids
    • 14.2.6. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Injection
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. Teva Pharmaceutical
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Hoffmann-La Roche Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Johnson and Johnson
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Amgen
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. AstraZeneca
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. Pfizer, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. Merck & Co.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Novartis AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Allergan plc
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. Eli Lilly and Company
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
    • 15.3.11. AbbVie
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
    • 15.3.12. BioDelivery Sciences International, Inc.
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis

List of Tables

  • Table 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 06: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 10: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 18: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 22: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 03: Global Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 04: Global Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 05: Global Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 06: Global Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 07: Global Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 08: Global Acute Migraine Treatment Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 09: Global Acute Migraine Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 10: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 11: North America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 12: North America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 13: North America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14: North America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 15: North America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 16: North America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 17: North America Acute Migraine Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 18: North America Acute Migraine Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 19: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 20: Europe Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 21: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 22: Europe Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 23: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 24: Europe Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 25: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 26: Europe Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 27: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 28: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 30: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 31: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 32: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 33: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 34: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 36: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 37: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 38: Latin America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 39: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 40: Latin America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 41: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 42: Latin America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 43: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 44: Latin America Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 45: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 46: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 47: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 48: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 49: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 50: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 51: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 52: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 53: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 54: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 55: Global Acute Migraine Treatment Market Share Analysis, by Company, 2021